These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7045 related articles for article (PubMed ID: 22822590)

  • 61. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
    Papavasileiou E; Prasad S; Freitag SK; Sobrin L; Lobo AM
    Ocul Immunol Inflamm; 2016; 24(2):140-6. PubMed ID: 25760920
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ipilimumab-induced encephalopathy with a reversible splenial lesion.
    Conry RM; Sullivan JC; Nabors LB
    Cancer Immunol Res; 2015 Jun; 3(6):598-601. PubMed ID: 25922203
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.
    Tarhini A; Lo E; Minor DR
    Cancer Biother Radiopharm; 2010 Dec; 25(6):601-13. PubMed ID: 21204754
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Atypical clinical response patterns to ipilimumab.
    Ledezma B; Binder S; Hamid O
    Clin J Oncol Nurs; 2011 Aug; 15(4):393-403. PubMed ID: 21810572
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.
    Klair JS; Girotra M; Hutchins LF; Caradine KD; Aduli F; Garcia-Saenz-de-Sicilia M
    Dig Dis Sci; 2016 Jul; 61(7):2132-9. PubMed ID: 26846115
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer.
    Genova C; Rijavec E; Barletta G; Sini C; Dal Bello MG; Truini M; Murolo C; Pronzato P; Grossi F
    Expert Opin Biol Ther; 2012 Jul; 12(7):939-48. PubMed ID: 22506716
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
    Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
    [TBL] [Abstract][Full Text] [Related]  

  • 68. T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.
    Del Vecchio M; Mortarini R; Tragni G; Di Guardo L; Bersani I; Di Tolla G; Agustoni F; Colonna V; Weber JS; Anichini A
    J Clin Oncol; 2011 Nov; 29(32):e783-8. PubMed ID: 21990398
    [No Abstract]   [Full Text] [Related]  

  • 69. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series.
    Min L; Vaidya A; Becker C
    Endocr Pract; 2012; 18(3):351-5. PubMed ID: 22138079
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
    Gaudy-Marqueste C; Monestier S; Franques J; Cantais E; Richard MA; Grob JJ
    J Immunother; 2013 Jan; 36(1):77-8. PubMed ID: 23211620
    [TBL] [Abstract][Full Text] [Related]  

  • 71. No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.
    Goff SL; Robbins PF; El-Gamil M; Rosenberg SA
    J Immunother; 2009 Oct; 32(8):884-5. PubMed ID: 19752745
    [No Abstract]   [Full Text] [Related]  

  • 72. [Possible Pitfalls of Ipilimumab Therapy in Malignant Melanoma -  a Case Report].
    Kopecký J; Kubeček O; Gabalec F; Hoffmann P; Svilias I
    Klin Onkol; 2015; 28(6):444-9. PubMed ID: 26673995
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association between ipilimumab and celiac disease.
    Gentile NM; D'Souza A; Fujii LL; Wu TT; Murray JA
    Mayo Clin Proc; 2013 Apr; 88(4):414-7. PubMed ID: 23541015
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP).
    King J; de la Cruz J; Lutzky J
    J Immunother Cancer; 2017; 5():19. PubMed ID: 28344807
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Compare and contrast.
    Prescrire Int; 2012 Jun; 21(128):144. PubMed ID: 22822589
    [No Abstract]   [Full Text] [Related]  

  • 76. Ipilimumab: first global approval.
    Cameron F; Whiteside G; Perry C
    Drugs; 2011 May; 71(8):1093-104. PubMed ID: 21668044
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient.
    Miserocchi E; Cimminiello C; Mazzola M; Russo V; Modorati GM
    Can J Ophthalmol; 2015 Feb; 50(1):e2-4. PubMed ID: 25677296
    [No Abstract]   [Full Text] [Related]  

  • 78. Severe meningo-radiculo-neuritis associated with ipilimumab.
    Bompaire F; Mateus C; Taillia H; De Greslan T; Lahutte M; Sallansonnet-Froment M; Ouologuem M; Renard JL; Gorochov G; Robert C; Ricard D
    Invest New Drugs; 2012 Dec; 30(6):2407-10. PubMed ID: 22231551
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature.
    Jose A; Yiannoullou P; Bhutani S; Denley H; Morton M; Picton M; Summers A; van Dellen D; Augustine T
    Transplant Proc; 2016 Nov; 48(9):3137-3141. PubMed ID: 27932166
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses.
    Torino F; Barnabei A; Paragliola RM; Marchetti P; Salvatori R; Corsello SM
    Eur J Endocrinol; 2013 Dec; 169(6):R153-64. PubMed ID: 24001893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 353.